VELABS THERAPEUTICS
Velabs Therapeutics is a pioneer in microfluidics-based technologies for functional screening of antibodies. Their high-throughput screening platform allows for testing millions of correctly paired fully natural IgGs from humans and mice for therapeutic effects, rather than just for binding. Rare functional hits are readily identified, which might be laborious or even impossible using other technologies. Velabs’ antibody screens can thus significantly and competitively shorten pre-clinical development.
VELABS THERAPEUTICS
Industry:
Biotechnology Health Care Medical
Founded:
2017-01-01
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.veraxa.de
Total Employee:
11+
Status:
Active
Contact:
+49 6221 387 8194
Total Funding:
3 M EUR
Technology used in webpage:
SPF IPv6 Microsoft Exchange Online Office 365 Mail Pound Sterling Japanese Yen Strato Strato DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cellsway
Cellsway is developing liquid biopsy platform which uses a simple blood sample for monitoring cancer.
MicroBrain Biotech
MicroBrain Biotech develops and designs microfluidic devices and Nerve-on-Chip (reconstructed neuron networks at the micron scale).
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
ScarTec Therapeutics
ScarTec Therapeutics develops novel peptide-based technology for scar-free healing.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Veramaris
Veramaris is a producer of omega-3 fatty acids for animal nutrition from microalgae.
VERAXA Biotech
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
Current Advisors List
Advisor
Advisor
Current Employees Featured
Martin Haase Chief Financial Officer & Executive, Strategy @ Velabs Therapeutics
Chief Financial Officer & Executive, Strategy
Edward Lemke Co-Founder @ Velabs Therapeutics
Co-Founder
Christoph Antz Co-Founder & Chief Executive Officer @ Velabs Therapeutics
Co-Founder & Chief Executive Officer
2017-12-01
Christine Köhler Dipl.-Ing., Co-Founder, Head of Biotechnology RD, Antibody Production @ Velabs Therapeutics
Dipl.-Ing., Co-Founder, Head of Biotechnology RD, Antibody Production
Christoph Merten Co-Founder & Chief Scientific Officer @ Velabs Therapeutics
Co-Founder & Chief Scientific Officer
Founder
Official Site Inspections
http://www.veraxa.de
- Host name: static.72.175.47.78.clients.your-server.de
- IP address: 78.47.175.72
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Velabs Therapeutics"
About us - Veraxa
VERAXA is a privately held company. Main shareholder is the Swiss company Xlife Sciences AG. Other shareholders are the European Molecular Biology Laboratory (EMBL) and its technology …See details»
Veraxa
Next-generation ADCs and novel antibody formats will take safety to the next level. With a strong foundation in ADCs and our lead program in clinical studies in AML. The VERAXA team is …See details»
Our approach - Veraxa
VERAXA is the only company with an integrated approach that combines functional antibody screening with bioconjugation technology. We harvest our suite of innovative technologies to …See details»
VERAXA Biotech GmbH - LinkedIn
Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for...See details»
VERAXA Biotech GmbH - BIO International Convention | BIO
VERAXA is an early-stage biotechnology company with game-changing antibody discovery, screening and conjugation technology yielding the most optimized Antibody Drug Conjugates …See details»
VERAXA - EMBLEM Technology Transfer GmbH
VERAXA combines game changing technologies developed at the EMBL Heidelberg to solve the most prominent challenges in antibody drug development. The VERAXA Biotech Company …See details»
VERAXA Biotech - Crunchbase Company Profile & Funding
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. A droplet-based microfluidics platform that combines …See details»
Veraxa Biotech - Org Chart, Teams, Culture & Jobs - The Org
View Veraxa Biotech's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
VERAXA Biotech - VentureRadar
Develops droplet-based microfluidic screening and protein conjugation technology for rapid generation of antibodies, focusing on oncology and precision medicine. Partners with global …See details»
VERAXA Biotech GmbH - Xlife Sciences
Veraxa Biotech AG focuses on the development of antibody-drug conjugates through an innovative click chemistry approach and the microfluidic screening of functional antibodies. …See details»
Veraxa Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Veraxa. Use the PitchBook Platform to explore the full profile.See details»
Veraxa
HEIDELBERG, Germany, January 29, 2024 -- VERAXA Biotech GmbH, an emerging leader in designing novel cancer immunotherapies, today provided an update on its pipeline …See details»
VERAXA Biotech - Funding, Financials, Valuation & Investors
Dec 29, 2023 · VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.See details»
VERAXA Biotech AG übernimmt Synimmune GmbH zur …
Dec 29, 2023 · Die VERAXA Biotech AG hat den FLYSYN-Antikörper von der Synimmune GmbH, einem Portfoliounternehmen von Xlife Sciences AG, über einen Aktiendeal erworben. Der …See details»
VERAXA Biotech GmbH – BioRN – Life Science Cluster Rhine-Neckar
VERAXA Biotech GmbH; September 10, 2024 . VERAXA Biotech GmbH. Go back Share this article: Original News Our latest News discover more . bioRN annual report 2024. read more . …See details»
Veraxa
HEIDELBERG, Germany, May 21, 2024 -- VERAXA Biotech GmbH, an emerging leader in designing novel cancer therapies, announced today the formation of a Clinical Advisory Board …See details»
velabs (VERAXA Biotech GmbH) - Startbase
Headquarter: Heidelberg, DE; Official Website: velabs-therapeutics.com; On Social Media: Legal Entity: VERAXA Biotech GmbH Location: SaarlandSee details»
VERAXA Biotech and Quadira Biosciences Enter Partnership on …
Jun 14, 2021 · VERAXA Biotech is a leading pioneer of microfluidic technology for the ultra-fast screening of functional antibodies. The company has developed superior microfluidic hardware …See details»
Veraxa
VERAXA is a preferred license and cooperation partner of global biotech and pharma industries. Contact. VERAXA Biotech GmbH Dr. Christoph Antz CEO Meyerhofstrasse 1 69117 …See details»
Working at Veraxa Biotech - Glassdoor
See what employees say it's like to work at Veraxa Biotech. Salaries, reviews, and more - all posted by employees working at Veraxa Biotech.See details»